HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOID POLYNEUROPATHY

Clinical trials for HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOID POLYNEUROPATHY explained in plain language.

Never miss a new study

Get alerted when new HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOID POLYNEUROPATHY trials appear

Sign up with your email to follow new studies for HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOID POLYNEUROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Extended trial tests if new nerve disease drug remains safe for years

Disease control Ongoing

This study follows patients who previously participated in earlier trials of eplontersen, a medication for hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN), a rare nerve disease. Researchers want to see if the drug remains safe and effective when taken for up t…

Matched conditions: HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOID POLYNEUROPATHY

Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control

Last updated Mar 30, 2026 14:33 UTC

HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOID POLYNEUROPATHY

Get alerted when new HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOID POLYNEUROPATHY trials appear

Extended trial tests if new nerve disease drug remains safe for years